712 related articles for article (PubMed ID: 15037985)
1. Pharmacological approach to diabetic retinopathy.
De La Cruz JP; González-Correa JA; Guerrero A; de la Cuesta FS
Diabetes Metab Res Rev; 2004; 20(2):91-113. PubMed ID: 15037985
[TBL] [Abstract][Full Text] [Related]
2. Management of proliferative diabetic retinopathy.
Gündüz K; Bakri SJ
Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy.
Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ
Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151
[TBL] [Abstract][Full Text] [Related]
4. [Results of laser photocoagulation in patients with diabetic retinopathy developed as a complication of diabetes type 2].
Wilczyński M; Dzivgielewski K
Klin Oczna; 2006; 108(1-3):66-9. PubMed ID: 16883944
[TBL] [Abstract][Full Text] [Related]
5. [Medical treatment in diabetic retinopathy].
Brănişteanu D; Graur M
Rev Med Chir Soc Med Nat Iasi; 2005; 109(2):230-5. PubMed ID: 16607776
[TBL] [Abstract][Full Text] [Related]
6. High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
Liinamaa MJ; Savolainen MJ
Ann Med; 2008; 40(3):209-14. PubMed ID: 18382886
[TBL] [Abstract][Full Text] [Related]
7. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
[TBL] [Abstract][Full Text] [Related]
8. Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.
Lip PL; Chatterjee S; Caine GJ; Hope-Ross M; Gibson J; Blann AD; Lip GY
Br J Ophthalmol; 2004 Dec; 88(12):1543-6. PubMed ID: 15548809
[TBL] [Abstract][Full Text] [Related]
9. Effects of stobadine and vitamin E in diabetes-induced retinal abnormalities: involvement of oxidative stress.
Yülek F; Or M; Ozoğul C; Isik AC; Ari N; Stefek M; Bauer V; Karasu C
Arch Med Res; 2007 Jul; 38(5):503-11. PubMed ID: 17560455
[TBL] [Abstract][Full Text] [Related]
10. [Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Freyberger H; Schifferdecker E; Schatz H
Med Klin (Munich); 1994 Nov; 89(11):594-7, 633. PubMed ID: 7815987
[TBL] [Abstract][Full Text] [Related]
11. Current approaches and perspectives in the medical treatment of diabetic retinopathy.
Porta M; Allione A
Pharmacol Ther; 2004 Aug; 103(2):167-77. PubMed ID: 15369682
[TBL] [Abstract][Full Text] [Related]
12. Visual prognosis after panretinal photocoagulation for proliferative diabetic retinopathy.
Bek T; Erlandsen M
Acta Ophthalmol Scand; 2006 Feb; 84(1):16-20. PubMed ID: 16445434
[TBL] [Abstract][Full Text] [Related]
13. [Diabetic retinopathy].
Grange JD
Rev Prat; 1996 Sep; 46(14):1714-21. PubMed ID: 8949278
[TBL] [Abstract][Full Text] [Related]
14. [Comparative study of the role of cytokines in various eye diseases. 2. Diabetic retinopathy].
Slepova OS; Gerasimenko VL; Zakharova GIu; Novikova-Bilak TI
Vestn Oftalmol; 2001; 117(3):35-7. PubMed ID: 11521435
[TBL] [Abstract][Full Text] [Related]
15. [The use of ticlid in diabetic retinopathy].
Rubtsova AL; Ametov AS; Strakhov VV
Ter Arkh; 1997; 69(10):19-21. PubMed ID: 9471782
[TBL] [Abstract][Full Text] [Related]
16. Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy.
Zakareia FA; Alderees AA; Al Regaiy KA; Alrouq FA
J Diabetes Complications; 2010; 24(3):179-85. PubMed ID: 19216096
[TBL] [Abstract][Full Text] [Related]
17. Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF).
Nicoletti VG; Nicoletti R; Ferrara N; Meli G; Reibaldi M; Reibaldi A
Exp Clin Endocrinol Diabetes; 2003 Jun; 111(4):209-14. PubMed ID: 12845559
[TBL] [Abstract][Full Text] [Related]
18. Relationship among VEGF, VEGF receptor, AGEs, and macrophages in proliferative diabetic retinopathy.
Kakehashi A; Inoda S; Mameuda C; Kuroki M; Jono T; Nagai R; Horiuchi S; Kawakami M; Kanazawa Y
Diabetes Res Clin Pract; 2008 Mar; 79(3):438-45. PubMed ID: 18053608
[TBL] [Abstract][Full Text] [Related]
19. Expression of vascular endothelial growth factor in proliferative diabetic retinopathy.
Merlak M; Kovacević D; Balog T; Marotti T; Misljenović T; Mikulicić M; Dekaris I
Coll Antropol; 2008 Oct; 32 Suppl 2():39-43. PubMed ID: 19138004
[TBL] [Abstract][Full Text] [Related]
20. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy.
Wang X; Wang G; Wang Y
Am J Ophthalmol; 2009 Dec; 148(6):883-9. PubMed ID: 19837381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
